Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dsuvia

- PMLiVE

Pfizer to sell off Hospira’s infusions business – and its New York HQ

Infusion therapy specialist ICU Medical buys up unit in $1bn deal

Celgene building

Celgene bolsters blood cancer portfolio with $600m EngMab buy

Consolidates position as top company in current multiple myeloma market

- PMLiVE

GSK draws line under Chinese scandal with $20m SEC settlement

Brings corruption investigation to an end with commitment to ongoing remediation reports

- PMLiVE

Man Boobs campaign wins at D&AD Impact Awards

Takes home White Pencil in inaugural awards for creative contribution to society

- PMLiVE

Novartis’ Ilaris wins three new FDA approvals

Immunotherapeutic expands in rare Periodic Fever Syndrome conditions

- PMLiVE

Kite Pharma soars after positive CAR-T data in lymphoma

Looks to become first marketed CAR-T drug as phase II results pave way for US filing

- PMLiVE

McCann Health creates new global consultancy

Former Novartis exec Simon Holt to head up Consulting at McCann Health

Sanofi reception

Sanofi eyes March approval for dupilumab in atopic dermatitis

Analysts suggest sales could reach $2.8bn annually if licensed in eczema and asthma

- PMLiVE

Amgen claims first US go-ahead for Humira biosimilar

Amjevita receives FDA approval but faces patent infringement lawsuit from AbbVie

- PMLiVE

Sarepta soars as FDA clears its muscular dystrophy drug

Analysts anticipate blockbuster status for DMD therapy despite efficacy concerns

Sanofi reception

Sanofi fires off another lawsuit against a Lantus biosimilar

Alleges patent infringement by Merck & Co’s biosimilar version filed in the US last month

EISAI

Eisai wins EU licence for kidney cancer drug Kisplyx

Approved as a second-line combination treatment for advanced RCC

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links